天然产物研究与开发 ›› 2016, Vol. 28 ›› Issue (6): 955-958.doi: 10.16333/j.1001-6880.2016.6.024

• 开发研究 • 上一篇    下一篇

介孔分子筛对传统药物的原位载药及缓释研究

朴丽锦,余燕敏,李华*,周珊珊,夏建新   

  1. 中央民族大学生命与环境科学学院,北京 100081
  • 出版日期:2016-06-30 发布日期:2017-01-17

Preparation and Sustained Release of New Traditional Drug Molecules by Self-Assembly Drug in Mesoporous Silica

PIAO Li-jin,YU Yan-min,LI Hua*,ZHOU Shan-shan,XIA Jian-xin   

  1. College of Life and Environmental Sciences,Minzu University of China,Beijing 100081,China
  • Online:2016-06-30 Published:2017-01-17

摘要: 利用原位组装法将水难溶性的治疗冠心病药物槲皮素组装进入到介孔分子筛MCM-41孔道中,重点考察了介孔分子筛对药物的原位组装率和缓释率,验证此载药体系的优势。用X射线粉末衍射仪、扫描电镜、红外光谱对组装材料进行表征。原位组装法制得的产物载药率最高达到93%[m(药物)/m(药物总量)],与后组装制得产物的组装率70%相比,有明显提高;测定体外模拟肠液中的缓释率,可知原位组装的产品释放总量约为13 h后基本不再释放,总量大概为93%,高于后组装产品(87.25%)。实验结果表明MCM41介孔分子筛原位组装槲皮素药物分子有明显优势。

关键词: MCM-41, 槲皮素, 原位组装, 缓释率

Abstract: Waterinsoluble drug for coronary heart disease (CHD),quercetin,was incorporated in MCM-41 channel by using in situ self-assembly method.The assembling materials were characterized by XRD,SEM and FT-IR techniques.The experimental results proved that drug assembling rate was 93% [m(drug)/m(total drug)],much higher than post-assembly method (70%).The release rate of the assemblies was 93% after around 13 h,which was measured in the artificial intestinal fluid.It was also higher than results of post-assembly drug system (87.25%).The results indicated that in-situ self-assembling quercetin/MCM-41 was an ideal system to prepare a controlled-release delivery system.

Key words: MCM-41, quercetin, in-situ assemble, release efficiency

中图分类号: 

O614